Legend Biotech Reports Strong Q1 2026 Results with 62% CARVYKTI Sales Growth and Reduced Net Loss
LEGN sits 60% above its 52-week low of $16.24.
Summary
Legend Biotech announced strong Q1 2026 financial results, highlighted by 62% growth in CARVYKTI sales and a significant reduction in net loss, reinforcing its path to profitability.
Key Events · Earnings and Guidance · LEGN
-
Strong CARVYKTI Sales Growth
Net trade sales of CARVYKTI increased 62% year-over-year to approximately $597 million in Q1 2026, with significant growth both in the U.S. and ex-U.S. markets.
-
Improved Profitability Metrics
Net loss significantly improved to $54.3 million in Q1 2026 from $101.0 million in Q1 2025. Adjusted net loss also improved to $10.5 million from $27.0 million in the prior year period.
-
Global Market Expansion
CARVYKTI is now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and Australia.
-
Operational Efficiencies
Manufacturing success rate for CARVYKTI increased to 99%, with decreased turnaround times and over 95% on-time order releases.
Analysis · LEGN · Life Sciences
Legend Biotech reported robust first-quarter 2026 financial results, driven by a significant 62% year-over-year increase in CARVYKTI sales to $597 million. The company also substantially narrowed its net loss and adjusted net loss, demonstrating improved operating performance and progress towards profitability. Global expansion of CARVYKTI and manufacturing efficiencies further underscore positive operational momentum.
At the time of this filing, LEGN was trading at $26.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $16.24 to $45.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.